CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma
- Disease/Condition
- Lymphoma
- Drug/Device/Intervention
- CD70-targeting CAR-T cells
- Study type
- Interventional
- Intervention type
- biological
- Primary sponsor
- Chinese PLA General Hospital
- Location
- Beijing, China
- Phase
- Phase 1/2
- Start date
- Jul 15, 2023
- End date
- Dec 31, 2026
- Enrollment
- 30 participants
Incidence of treatment related adverse events（AEs）,Incidence of dose limiting toxicities (DLTs),Maximum tolerated dose (MTD)
In this single-center, single-arm,prospective, open-label, phase 1/2 study, the safety and
 efficacy of autologous CD70 targeted chimeric antigen receptor modified T (CAR-T) cell
 therapy will be evaluated in patients with CD70 antigen positive Relapsed/Refractory Lymphoma
 . In this clinical trial, at least 12 eligible patients in dose escalation period will be
 enrolled to receive 3 doses of CD70-CAR cell therapy according to the 3+3 principle. In
 dose expansion period, additional at most 21 eligible patients will be enrolled to receive
 CD70-CAR-T cell therapy at dose of recommended phase 2 dose(RP2D).
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT05948033
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT05948033 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Chinese PLA General Hospital and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 30 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.